Results 81 to 90 of about 27,191 (241)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]

open access: yes, 2013
Keohane C, Radia DH, Harrison CN. Biologics: Targets and Therapy. 2013;7:189–198. On page 193 note that the paragraph beginning "Pacritinib (SB1518; Cell Technology, Inc, Mountain View, CA, USA) is a JAK2 and FLT3 inhibitor currently being ...
Keohane C, Radia DH, Harrison CN
core  

Primary Myelofibrosis - 1

open access: yes, 2014
An image showing tear cells and elliptocytes in primary myelofibrosis under 50X ...
Fraser, Marion
core   +1 more source

Treatment Algorithm for Primary and Secondary Myelofibrosis

open access: yes, 2023
The management of primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (PPV-MF), and postessential thrombocythemia (PET-MF) is driven by their clinicopathologic and genomic characteristics, and their risk categories.
Gill, Harinder, Leung, Garret
core   +1 more source

Primary autoimmune myelofibrosis: a report of three cases and review of the literature

open access: yesTurkish Journal of Hematology, 2009
Myelofibrosis in association with autoimmune disorders has been consistently recognized in sporadic case reports over a number of years. Autoimmune myelofibrosis has been described most commonly in association with systemic lupus erythematosus (SLE).
Rakhee Kar, Shyamali Dutta, Seema Tyagi
doaj  

Clinical and laboratory features at diagnosis of 132 patients with prefibrotic myelofibrosis compared with those with primary myelofibrosis-fibrotic type.

open access: yes, 2013
§P value refers to the difference between prefibrotic myelofibrosis and myelofibrosis-fibrotic type;§§P value refers to the difference between prefibrotic myelofibrosis and myelofibrosis-fibrotic type with bone marrow (BM) fibrosis grade 1;§§§P value ...
Paolo Catarsi (325689)   +12 more
core   +1 more source

Myelofibrosis [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1952
R B, FRANKS, J S, RICHARDSON
openaire   +2 more sources

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

open access: yesAdvanced Science, Volume 13, Issue 35, 24 June 2026.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Amyloidosis complicating idiopathic myelofibrosis.

open access: yes, 1999
An 84-year-old man presented with ankle edema, significant proteinuria, and mild impairment of renal function soon after treatment was started for idiopathic myelofibrosis. Renal amyloidosis was found on biopsy.
Ho, CP, Chan, KW
core   +1 more source

Digital PCR - Methods and Protocols

open access: yesEuropean Journal of Histochemistry, 2019
Sensitivity, reproducibility, precision and accuracy are recurring words in this book. Indeed, digital PCR (dPCR) represents a major step forward in the quantification of nucleic acids. In this field, for many years it has been used the quantitative PCR (
Paolo Catarsi
doaj   +1 more source

Home - About - Disclaimer - Privacy